Browsing Sydney Health Ethics by Title

15 minute consultation: an evidence-based approach to research without prior consent (deferred consent) in neonatal and paediatric critical care trials

Woolfall, K; Frith, L; Dawson, Angus; Gamble, C; Lyttle, M D; Young, B (BMJ Publishing Group, 2015)

What do we mean by research without prior consent (deferred consent)? Emergency research with critically unwell children is vital to make sure that the most ill and injured children benefit from evidence-based healthcare.1 ...

Abandoning clinical trial safeguards won’t boost local industry

Komesaroff, P; Thomson, C; Kerridge, I (The Conversation, 2013-10-07)

Testing new drugs in clinical trials is a billion-dollar industry in Australia, with most of the money coming from international pharmaceutical companies. But as investment grows in India, China, and other emerging ...

Academics on the payroll: the advertising you don’t see

Lipworth, W; Kerridge, I (The Conversation, 2014-06-18)

In the endless drive to get people’s attention, advertising is going ‘native’, creeping in to places formerly reserved for editorial content. In this Native Advertising series we find out what it looks like, if readers can ...

Accelerated access to medicines: An ethical analysis

Pace, J; Ghinea, N; Kerridge, I; Lipworth, W (Sage, 2017)

In recent years, a range of initiatives have been introduced to provide patients with access to medicines outside of traditional regulatory and/or funding channels; we term these processes “accelerated access to medicines”. ...

Access to high cost cancer medicines through the lens of an Australian Senate Inquiry - defining the 'goods' at stake.

Ghinea, N; Little, M; Lipworth, W (Springer, 2017)

In Australia, the government is the primary payer for cancer medicines, and is supported by the Pharmaceutical Benefits Advisory Committee, which makes recommendations about which medicines should be funded on the ...

Access to new cancer medicines in Australia: dispelling the myths and informing a public debate

Vitry, A; Mintzes, B; Lipworth, W (BMC, 2016)

Despite the high level of spending on cancer medicines in Australia, consumer organisations and the pharmaceutical industry often make claims of delayed or lack of access to new cancer medicines—claims that are frequently ...

Access to the Kidney Transplant Waiting List – a time for reflection

Pussell, B; Bendorf, A; Kerridge, I (Wiley, 2012)

The limited availability of deceased donor kidneys for transplantation in Australia continues to be a matter of concern. Analysis of registry data suggests that the current renal transplant waiting list under-represents ...

Addressing health inequities for same sex attracted women in New South Wales, Australia, who use drugs

Matheson, A; May, S; Mooney-Somers, Julie; Deacon, Rachel M. (ACON, 2011)

ACON’s Alcohol and Other Drugs Program provides a Needle Syringe Program, peerbased harm reduction programs, drug education targeted at members of the lesbian, gay, bisexual and transgender (LGBT) community, and counselling ...

Addressing health inequities for same sex attracted women in New South Wales, who use drugs (APSAD).

Matheson, A; Ishter, T; May, S; Mooney-Somers, Julie; Deacon, R (ACON, 2011-11)

ACON’s Alcohol and Other Drugs Program provides a Needle Syringe Program, peer-based harm reduction programs, drug education targeted at members of the gay, lesbian, bisexual and transgender (GLBT) community, and counselling ...

Adherence to cancer screening guidelines in Australian survivors of allogeneic blood and marrow transplantation (BMT)

Dyer, G; Larsen, S.R; Gilroy, Nicole; Brice, Lisa; Greenwood, Matt; Hertzberg, Mark; Kabir, Masura; Brown, Louisa; Hogg, Megan; Huang, Gillian; Moore, John; Gottlieb, David; Kwan, John; Tan, Jeff; Ward, Christopher; Kerridge, I (Wiley, 2016-04-25)

Allogeneic Blood and Marrow Transplant (BMT) survivors are at high risk of secondary cancers. Although current guidelines endorse survivors following Country-specific general population screening recommendations to ...

Advance care planning for cancer patients: A systematic review of perceptions and experiences of patients, families and healthcare providers

Johnson, S; Butow, P; Kerridge, I; Tattersall, M (Wiley, 2015-09)

Background Patients with advanced cancer may benefit from end of life (EOL) planning, but there is evidence that their willingness and desire to engage in advance care planning (ACP) varies. The reasons for this remain ...

Aesthetics for Visual Arts in Hospitals

Gates, Jillian Marie (University of Sydney., 2011-05-16)

The impetus for Aesthetics for Art in Hospitals emerged from my first waiting experiences in hospitals whilst being well, from my first pregnancy check ups ten years ago, accompanying my children to our doctor’s surgery, ...

Affordable access to innovative cancer medicines — don’t forget the prices

Ghinea, N; Lipworth, W (AmpCo., 2016)

On 17 September 2015, the much anticipated Senate report on the and specialist cancer drugs in Australia Availability of new, innovative was released.1 The inquiry preceding the report, which was triggered by concerns ...

The Age of Genomics

Newson, A.J. (Control Publications Pty Ltd., 2016-08)

This edition of Australasian Science focuses on the ethical, legal and social issues associated with advances in genomic science. Faster and more accurate sequencing of human genomes; smaller and smarter wearable technologies; ...

An Agrarian Imaginary in Urban Life: Cultivating Virtues and Vices Through a Conflicted History.

Mayes, C (Springer, 2013)

This paper explores the influence and use of agrarian thought on collective understandings of food practices as sources of ethical and communal value in urban contexts. A primary proponent of agrarian thought that this ...

All care, but whose responsibility? Community juries reason about expert and patient responsibilities in prostate-specific antigen screening for prostate cancer

Degeling, C; Carter, SM; Rychetnik, L (Sage, 2016-08-03)

General practitioners have implicitly been given responsibility for guiding men’s decisions about prostate-specific antigen–based screening for prostate cancer, but patients’ expectations of the bounds of this responsibility ...